Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer
January 25, 2024
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer
Exceeding Anticipated Timelines with Accelerated Momentum
- Interim Data Analysis Anticipated in Mid-2024
- Expects Full Enrollment by Q1 2025